Welcome to Paid Research Studies




  • Condition:   Dwarfism
    Interventions:   Drug: Jintrolong® low dose group;   Drug: Jintrolong® high dose group
    Sponsors:   GeneScience Pharmaceuticals Co., Ltd.;   Tongji Hospital;   First Hospital of Jilin University;   Affiliated Hospital of Jiangnan University;   The First Affiliated Hospital with Nanjing Medical University;   Shanghai Children's Hospital;   The Children's Hospital of Zhejiang University School of Medicine;   Children's Hospital of Fudan University
    Recruiting - verified July 2017

  • Conditions:   HIV Lipodystrophy Syndrome;   Growth Hormone Deficiency;   Body Composition
    Intervention:   Drug: Tesamorelin
    Sponsors:   Columbia University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified July 2017

  • Condition:   Growth Hormone Deficiency
    Intervention:   Drug: Growth hormone
    Sponsors:   Columbia University;   Novo Nordisk A/S
    Recruiting - verified July 2017

  • Conditions:   Taybi Linder Syndrome;   Genetic Syndrome
    Intervention:   Genetic: Deoxyribonucleic acid analysis
    Sponsor:   Hospices Civils de Lyon
    Not yet recruiting - verified July 2017

  • Conditions:   Growth Hormone Disorder;   Adult Growth Hormone Deficiency;   Growth Hormone Deficiency in Children
    Intervention:   Drug: Somapacitan
    Sponsor:   Novo Nordisk A/S
    Not yet recruiting - verified July 2017

  • Conditions:   Growth Hormone Disorder;   Adult Growth Hormone Deficiency;   Growth Hormone Deficiency in Children
    Intervention:   Drug: Somapacitan
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified June 2017

  • Condition:   Zinc; Deficiency With Anemia
    Intervention:   Diagnostic Test: serum zinc and iron
    Sponsor:   Assiut University
    Not yet recruiting - verified April 2017

  • Condition:   Growth Hormone Deficiency
    Intervention:   Drug: Somavaratan
    Sponsor:   Versartis Inc.
    Recruiting - verified May 2017

  • Condition:   Adult Growth Hormone Deficiency
    Intervention:   Drug: Somatropin Injection
    Sponsors:   GeneScience Pharmaceuticals Co., Ltd.;   Peking Union Medical College Hospital;   Peking University First Hospital;   Hebei General Hospital;   The Second Hospital of Hebei Medical University;   Qilu Hospital of Shandong University;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   The First Affiliated Hospital of Soochow University;   First Affiliated Hospital of Chongqing Medical University;   Chongqing Three Gorges Central Hospital;   West China Hospital
    Recruiting - verified March 2017

  • Conditions:   Short Stature;   Growth Disorders
    Interventions:   Device: SonicBone Ultrasound;   Device: Wrist X-ray
    Sponsor:   Meir Medical Center
    Not yet recruiting - verified February 2017

  • Conditions:   Growth Hormone Disorder;   Adult Growth Hormone Deficiency
    Interventions:   Drug: somapacitan;   Drug: Norditropin
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified June 2017

  • Conditions:   IGHD - Isolated Growth Hormone Deficiency;   Growth Retardation
    Interventions:   Dietary Supplement: Nutritional supplementation standardized formula;   Dietary Supplement: Placebo
    Sponsor:   Rabin Medical Center
    Not yet recruiting - verified April 2017

  • Condition:   Cockayne Syndrome
    Intervention:   Other: Metabolic evaluation
    Sponsor:   University Hospital, Strasbourg, France
    Not yet recruiting - verified February 2017

  • Conditions:   Epidermolysis Bullosa Simplex;   Epidermolysis Bullosa Simplex Kobner;   Weber-Cockayne Syndrome
    Interventions:   Drug: Sirolimus 2%;   Drug: Vehicle
    Sponsor:   Premier Specialists, Australia
    Recruiting - verified January 2017

  • Condition:   Fitness
    Intervention:   Other: change in fitness level
    Sponsor:   Meir Medical Center
    Not yet recruiting - verified November 2016

  • Conditions:   Growth Hormone Deficiency;   Attention Deficit Disorder;   Idiopathic Short Stature
    Intervention:   Other: Questionnaires
    Sponsor:   Assaf-Harofeh Medical Center
    Recruiting - verified November 2016

  • Condition:   Growth Hormone Deficiency
    Interventions:   Biological: PEG-somatropin;   Biological: PEG-somatropin
    Sponsors:   GeneScience Pharmaceuticals Co., Ltd.;   Children's Hospital of Fudan University;   Suzhou Municipal Hospital;   General Hospital of Ningxia Medical University;   The First Affiliated Hospital of Henan University of Science and Technology;   Maternal and Child Health Hospital of Hubei Province;   Nantong University
    Recruiting - verified November 2016

  • Condition:   Adult-Onset Growth Hormone Deficiency
    Intervention:  
    Sponsor:   Garcia, Jose M., MD, PhD
    Recruiting - verified December 2016

  • Condition:   Pediatric Growth Hormone Deficiency
    Interventions:   Drug: MOD-4023;   Drug: Somatropin
    Sponsor:   Opko Biologics
    Recruiting - verified October 2016

  • Conditions:   Short Stature, Idiopathic;   Infant, Small for Gestational Age;   Growth Hormone Deficiency;   Chronic Renal Failure;   Turner Syndrome
    Intervention:   Drug: Somatropin
    Sponsor:   LG Life Sciences
    Recruiting - verified January 2017

  • Condition:   Growth Hormone Deficiency
    Interventions:   Biological: PEG-somatropin;   Biological: PEG-somatropin
    Sponsors:   GeneScience Pharmaceuticals Co., Ltd.;   The Children's Hospital of Zhejiang University School of Medicine;   The Second Hospital of Anhui Medical University;   Guangzhou Women and Children's Medical Center;   First People's Hospital of Hangzhou;   Qilu Hospital of Shandong University;   Zhejiang Provincial People’s Hospital;   Zhejiang Provincial Hospital of TCM;   Central South University;   Southwest Hospital, China;   First Affiliated Hospital of Guangxi Medical University;   Shanghai Children's Medical Center;   Second Affiliated Hospital of Wenzhou Medical University;   The First Affiliated Hospital of Xiamen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Xiangya Hospital of Central South University;   Shaoxing Second Hospital
    Recruiting - verified September 2016

  • Condition:   Short Stature
    Interventions:   Drug: propofol and remifentanil;   Drug: desflurane and remifentanil
    Sponsor:   Yonsei University
    Recruiting - verified December 2016

  • Conditions:   Epidermolysis Bullosa Simplex;   Epidermolysis Bullosa Simplex Kobner;   Weber-Cockayne Syndrome
    Interventions:   Drug: Sirolimus, 2%;   Drug: Vehicle
    Sponsor:   Stanford University
    Recruiting - verified November 2016

  • Conditions:   Growth Hormone Deficiency, Pediatric;   hGH (Human Growth Hormone);   Endocrine System Diseases;   Hormones;   Pituitary Diseases
    Interventions:   Drug: Once weekly subcutaneous injection of TransCon hGH;   Drug: Once daily subcutaneous injection of Genotropin
    Sponsor:   Ascendis Pharma A/S
    Recruiting - verified November 2016

  • Condition:   Adult Growth Hormone Deficiency (AGHD)
    Intervention:   Drug: somavaratan
    Sponsors:   Versartis Inc.;   Premier Research Group plc
    Recruiting - verified August 2016

  • Conditions:   Adrenal Insufficiency;   Congenital Adrenal Hyperplasia;   Cushing Syndrome;   Growth Hormone Deficiency;   Acromegaly;   Primary Hyperaldosteronism
    Intervention:   Other: 27 hour subcutaneous fluid sampling
    Sponsors:   Haukeland University Hospital;   Karolinska Institutet;   University Hospitals Bristol NHS Foundation Trust;   Evaggelismos Hospital, Greece
    Not yet recruiting - verified October 2016

  • Conditions:   Growth Hormone Disorder;   Growth Hormone Deficiency in Children
    Interventions:   Drug: NNC0195-0092;   Drug: Norditropin® FlexPro® pen
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified June 2017

  • Conditions:   Pediatric Growth Hormone Deficiency;   Growth Disorders
    Intervention:   Drug: Somavaratan (VRS-317)
    Sponsor:   Versartis Inc.
    Recruiting - verified November 2016

  • Conditions:   Growth Problem;   Low Weight;   Short Stature
    Interventions:   Dietary Supplement: Nutritional supplementation standardized formula;   Dietary Supplement: Placebo comparator
    Sponsor:   Rabin Medical Center
    Recruiting - verified January 2017

  • Condition:   Growth Hormone Deficiency
    Interventions:   Biological: PEG-somatropin;   Biological: PEG-somatropin
    Sponsor:   GeneScience Pharmaceuticals Co., Ltd.
    Recruiting - verified June 2017

  • Conditions:   Short Stature;   Growth Disorder
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified October 19, 2016

  • Condition:   Pediatric Growth Hormone Deficiency
    Intervention:   Drug: somavaratan
    Sponsor:   Versartis Inc.
    Recruiting - verified September 2016

  • Condition:   Short Stature
    Intervention:   Other: Anaerobic Test
    Sponsor:   Meir Medical Center
    Recruiting - verified September 2016

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated
    Recruiting - verified September 2016

  • Condition:   Achondroplasia
    Intervention:  
    Sponsor:   BioMarin Pharmaceutical
    Recruiting - verified June 2017

  • Conditions:   Idiopathic Short Stature;   Self Image
    Interventions:   Drug: GH treatment (Genotropin);   Drug: 1 year treatment with placebo followed by optional 3 years of GH treatment
    Sponsors:   Rabin Medical Center;   Pfizer
    Recruiting - verified January 2017

  • Conditions:   Obesity;   Short Stature;   Growth Hormone Deficiency
    Interventions:   Drug: Niacin;   Drug: Placebo
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified June 2, 2017

  • Conditions:   Chromosome Aberrations;   Growth Hormone Deficiency;   Hypomyelination
    Interventions:   Procedure: Determination of growth hormone status;   Procedure: Measurement of growth, thyroid and sex hormone levels;   Procedure: Behavior and neuropsychometric evaluations;   Procedure: Audiological and ear, nose and throat examination;   Procedure: Magnetic resonance imaging of the brain;   Procedure: Dysmorphology evaluation;   Procedure: Neurology examination;   Procedure: Dental evaluation;   Procedure: Speech pathology evaluation;   Procedure: Psychiatric evaluation;   Procedure: Orthopedic evaluation;   Procedure: Ophthalmologic evaluation;   Procedure: Gastrointestinal evaluation
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting - verified September 2016

  • Conditions:   Dwarfism;   Osteogenesis Imperfecta
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified February 9, 2017

  • Conditions:   Cockayne Syndrome;   Skin Cancer;   Xeroderma Pigmentosum;   Trichothiodystrophy;   Genodermatosis
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 11, 2017